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Mast cell increases and activation are detected in the chronic inflammatory bladder disease interstitial cystitis (IC), and their pro-
inflammatory mediators are felt to contribute to regional pelvic pain and inflammatory pathophysiology. The immunoreceptor 
tyrosine-based inhibition motif-containing sialic acid-binding immunoglobulin-like lectins (Siglecs) expressed in mast cells could 
be evaluated as in vivo signaling regulators capable of inhibiting IC-related mast cell activation.
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Interstitial cystitis (IC) is a chronic bladder inflammatory dis-
ease that is characterized by symptoms such as urinary urgency, 
frequency, nocturia, and suprapubic and pelvic pain and that 
mainly affect women. Although the exact etiology and patho-
genesis of IC is unknown, one etiologic theory that has been 
dominantly reported in relation to the bladder immune is that 
of a localized allergic reaction [1,2]. As reviewed by Theoharides 
et al. [1] and Rudick et al. [2], both clinical and experimental 
evidence show that IC is closely associated with an accumula-
tion of mast cells and their activation, especially in the detrusor, 
lamina propria, and submucosa. This theory was first introduced 
after the beneficial therapeutic use of antihistamines in IC pa-
tients [3]. Recently, detrusor mast cell migration and activation 
and urinary histamine metabolites have been detected in IC 
patients and in experimentally induced animal models [4-6]. 
Concerning these points, both the bladder pathophysiology 
and pelvic pain are dependent on mast cells. However, whereas 
pharmacological modulators of histamine receptors can be 
evaluated as therapeutic agents to improve chronic pelvic pain, 
they do not act on the pathophysiology, which is mediated by 
tumor necrosis factor (TNF)-α. These results indicate different 
causative factors for bladder pain and the pathophysiological 
inflammation [2]. 
  Mast cells are well known to be involved in both acute and 
chronic forms of allergic, type I hypersensitivity reactions. Mast 
cells are highly granulated cells that populate tissues including 
muscles and mucosal surfaces. Mast cells matured in these tis-
sues are partially or completely degranulated by a wide range of 
immunologic and nonimmunologic stimuli. After activation, a 
characteristic pattern of mast cell mediators is released during 
degranulation. These include preformed granule-associated in-
flammatory mediators (e.g., histamine, heparin, neutral prote-
ases, proteoglycans, glycoprotein-like YKL-40, chemotactic sub-
stances, and cytokines such as TNF-α), newly synthesized me-
diators (e.g., prostaglandin D2 [PGD2], leukotriene B4 and C4, 
interleukin-6 [IL-6], platelet-activating factor, and nitric oxide), 
and potent vasodilatory mediators (e.g., vasoactive intestinal 
peptide) [1,7,8]. These mast cell-released mediators are impli-
cated in causing IC bladder pathophysiology (e.g., apoptotic le-
sions in the urothelium and urothelial or mucosal barrier dys-
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function) and bladder-associated pelvic pain. Furthermore, the 
serum and urine levels of a new biomarker YKL-40, which is 
expressed in bladder mast cells, can be evaluated as an inflam-
matory mediator of bladder fibrogenesis in IC patients [8]. Also, 
IL-6 released from mature mast cells is elevated in the urine of 
IC patients and is highly increased in such patients with severe 
inflammation [9]. Thus, direct control via mast cell death or 
physiological blockade of bladder mast cell function is a reason-
able strategy for reducing the severity of IC.
  Mast cell survival and activation, which are mediated mainly 
by phosphorylation signals, can be negatively regulated by en-
gaging the inhibitory receptors (IRs) containing immunorecep-
tor tyrosine-based inhibitory motifs (ITIMs). Upon activation, 
the tyrosine residues of the ITIM sequences of the IRs are phos-
phorylated by the Src family of protein kinases [10]. The tyro-
sine phosphorylation typically induces recruitment of phospha-
tases, such as SHP-1 and SHP-2, and SH2-containing inositol 
phosphatases to the plasma membrane, which are then activat-
ed. Mast cell degranulation, for example as induced via FcεRI, 
is inhibited by this phosphatase-induced dephosphorylation 
mechanism [11]. 
  A classic form of several IRs on human mast cells is FcγRIIB, 
which can down-regulate mast cell activation when co-ligated 
with high-affinity IgE receptor (FcεRI) [7]. In addition to the 
classic FcγRIIB form, mast cells also express one or more ITIM 
sequence-containing IRs, such as sialic acid-binding immuno-
globulin-like lectins (Siglecs), on the cell surface to regulate their 
inflammatory or allergic activation. In this short review, we in-
troduce the potential application of Siglec antibodies to the mast 
cells to activate Siglec IRs in the inflammatory urinary bladder 
disease IC. 
  Siglecs are members of an immunoglobulin superfamily. 
They are type 1 transmembrane proteins containing a unique 
N-terminal ‘V-set’ Ig domain that can bind sialic acid and vari-
able numbers of extracellular ‘C2-set’ Ig domains. Most Siglecs 
(CD22 [Siglec-2]- and CD33 [Siglec-3]-related forms) also have 
a conserved cytosolic domain containing single or repeated IT-
IMs or ITIM-like motif sequences that are actively phosphory-
lated and that display inhibitory signaling functions. In particu-
lar, the genes for the CD33-related Siglecs (Siglec-3, -5, -6, -7, 
-8, -9, and -10) are located on chromosome 19 and have one or 
two ITIM sequences [12-14]. These Siglecs have been implicat-
ed mainly in the functional regulation of leukocytes via trigger-
ing signals via their ITIMs. Indeed, an important role of the 
CD33-related Siglecs is to regulate cell expansion by inhibiting 
or inducing apoptosis in leukocytes, but there are no reports of 
such activity in mast cells. 
  In human mast cells, CD22 (Siglec-2), CD33 (Siglec-3), and 
Siglecs-5 though -10 [15,16] are expressed at differential levels. 
In particular, the expression of the eosinophil-selective Siglec-8 
is also found weakly on basophils but prominently on mast cells. 
In functional experiments, activation of Siglec-8 by a specific 
monoclonal antibody (mAb) induced eosinophil apoptosis via 
caspase- and reactive oxygen species (ROS)-dependent pro-
cesses. In contrast, these antibodies failed to induce mast cell 
apoptosis but did inhibit by at least 50% histamine and PGD2 
release triggered via FcεRI. Additionally, in studies with human 
mast cells and Siglec-8 transfected RBL cells, activation (cross-
linking) of Siglec-8 with mAb inhibited IgE receptor-mediated 
beta hexosaminidase release and calcium influx, the latter of 
which is required for mast cells degranulation [17,18]. Indeed, 
normal human mast cells like LAD2 cells dominantly express 
Siglec-6 and -7 and moderately express Siglec-3 and -5, although 
expression is variable according to the culture stages of the mast 
cells. In our in vitro preliminary study in LAD2 cells, crosslink-
ing of each of these Siglecs before FcεRI-stimulation, or simul-
taneously co-crosslinking a given Siglec mAb and IgE, partially 
inhibited histamine secretion [unpublished data]. As suggested 
also by Bochner [19], activation of Siglecs other than Siglec-8 
would be expected to inhibit ITAM (immunoreceptor tyrosine-
based activating motif)-dependent secretory responses in mast 
cells. Therefore, activating mast cell Siglecs with specific mAbs, 
or glycan liagnds specific for a particular Siglec) could be used 
to down-regulate mast cell function.
  Increased numbers and activation of urinary bladder mast 
cells are major contributors to the pathophysiology of both ul-
cer and non-ulcer IC and in toxin- or chemical-induced animal 
models of IC. Although there are no reports targeting Siglecs or 
other mast cell IRs as a treatment for IC, the identification of 
these IRs on bladder infiltrated-mast cells would further our 
understanding of the mast cell phenotype in this disease, and 
may provide enthusiasm for the utilization of Siglec-specific 
mAbs or their glycan ligands to deliver inhibitory signals in vivo 
to mast cells as a potential treatment to reduce IC-induced blad-
der mast cell expansion and activation.
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